Literature DB >> 25194591

A single, low dose oral antigen exposure in newborn piglets primes mucosal immunity if administered with CpG oligodeoxynucleotides and polyphosphazene adjuvants.

J Alex Pasternak1, Siew Hon Ng2, Heather L Wilson3.   

Abstract

By definition, soluble antigens ingested orally trigger mucosal tolerance such that any subsequent re-exposure by a systemic route results in suppression of immunity. We propose that antigens introduced in extreme early life can readily traverse the gut wall and therefore circumvent induction of mucosal tolerance and instead induce immunity. Piglets were drenched with low-doses of ovalbumin (OVA; 5mg or 0.05 mg) alone, OVA plus adjuvants (CpG oligodeoxynucleotides and PCEP polyphosphazene) or saline within 6h of birth. At 28 days of age, they were administered 10mg OVA plus 1:1 Montanide adjuvant (or saline) via the intraperitoneal (i.p.) route or via the oral route. Serum was obtained on day 28 and day 49 to measure OVA-specific antibodies titres. All piglets boosted orally with OVA plus Montanide, regardless of prior OVA exposure, failed to induce immunity. As expected, piglets drenched with saline but boosted via the i.p. route with OVA plus Montanide showed significant induction of anti-OVA IgA, IgG, IgG1 and IgG2 relative to saline control piglets. Newborn animals drenched with 5mg or 0.05 mg OVA failed to induce oral immunity. A second intramuscular injection in adulthood triggered immunity in the piglets that were drenched with 0.05 mg OVA and boosted initially by the i.p. route suggesting that some systemic lymphocytes were primed despite initial lack of induction of humoral immunity. In contrast, piglets orally immunized with 5mg or 0.05 mg OVA plus adjuvants resulted in significant induction of anti-OVA IgA (5mg only), IgM, IgG, IgG1 and IgG2 in serum relative to saline control piglets as well as significant induction of anti-OVA IgA, IgM (5mg only) IgG, IgG1 (5mg only) or IgG2 relative to piglets drenched with OVA alone. These data clearly show that the response was sensitive to the oral vaccine components and was not simply a response to the i.p. immunization at day 28. This work demonstrates that newborn piglets respond to oral antigens with immunity if re-exposure to the antigen occurs via a systemic route and if adjuvants are included with the oral vaccine administered at birth. These results should be further explored to establish whether early life oral vaccination can be exploited to protect this susceptible population against infectious diseases.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Humoral; Mucosal immunity; Oral; Ovalbumin; Piglets; Priming

Mesh:

Substances:

Year:  2014        PMID: 25194591     DOI: 10.1016/j.vetimm.2014.08.006

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  4 in total

Review 1.  Polyphosphazene immunoadjuvants: Historical perspective and recent advances.

Authors:  Alexander K Andrianov; Robert Langer
Journal:  J Control Release       Date:  2020-12-05       Impact factor: 9.776

2.  Oral antigen exposure in newborn piglets circumvents induction of oral tolerance in response to intraperitoneal vaccination in later life.

Authors:  J Alex Pasternak; Siew Hon Ng; Rachelle M Buchanan; Sonja Mertins; George K Mutwiri; Volker Gerdts; Heather L Wilson
Journal:  BMC Vet Res       Date:  2015-03-07       Impact factor: 2.741

3.  Oral vaccination of piglets against Mycoplasma hyopneumoniae using silica SBA-15 as an adjuvant effectively reduced consolidation lung lesions at slaughter.

Authors:  Marina L Mechler-Dreibi; Henrique M S Almeida; Karina Sonalio; Mariela A C Martines; Fernando A M Petri; Beatriz B Zambotti; Marcela M Ferreira; Gabriel Y Storino; Tereza S Martins; Hélio J Montassier; Osvaldo A Sant'Anna; Márcia C A Fantini; Luís Guilherme de Oliveira
Journal:  Sci Rep       Date:  2021-11-17       Impact factor: 4.379

Review 4.  Evidence for a common mucosal immune system in the pig.

Authors:  Heather L Wilson; Milan R Obradovic
Journal:  Mol Immunol       Date:  2014-09-18       Impact factor: 4.407

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.